Authors:
Paliard, X
Doe, B
Selby, MJ
Hartog, K
Lee, AY
Burke, RL
Walker, CM
Citation: X. Paliard et al., Induction of herpes simplex virus gB-specific cytotoxic T lymphocytes in TAP1-deficient mice by genetic immunization but not HSV infection, VIROLOGY, 282(1), 2001, pp. 56-64
Authors:
Bard, F
Cannon, C
Barbour, R
Burke, RL
Games, D
Grajeda, H
Guido, T
Hu, K
Huang, JP
Johnson-Wood, K
Khan, K
Kholodenko, D
Lee, M
Lieberburg, I
Motter, R
Nguyen, M
Soriano, F
Vasquez, N
Weiss, K
Welch, B
Seubert, P
Schenk, D
Yednock, T
Citation: F. Bard et al., Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimerdisease, NAT MED, 6(8), 2000, pp. 916-919
Authors:
Marshall, GS
Li, MT
Stout, GG
Louthan, MV
Duliege, AM
Burke, RL
Hunt, LA
Citation: Gs. Marshall et al., Antibodies to the major linear neutralizing domains of cytomegalovirus glycoprotein B among natural seropositives and CMV subunit vaccine recipients, VIRAL IMMUN, 13(3), 2000, pp. 329-341
Authors:
O'Hagan, D
Goldbeck, C
Ugozzoli, M
Ott, G
Burke, RL
Citation: D. O'Hagan et al., Intranasal immunization with recombinant gD2 reduces disease severity and mortality following genital challenge with herpes simplex virus type 2 in guinea pigs, VACCINE, 17(18), 1999, pp. 2229-2236
Authors:
Corey, L
Langenberg, AGM
Ashley, R
Sekulovich, RE
Izu, AE
Douglas, JM
Handsfield, HH
Warren, T
Marr, L
Tyring, S
DiCarlo, R
Adimora, AA
Leone, P
Dekker, CL
Burke, RL
Leong, WP
Straus, SE
Citation: L. Corey et al., Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection - Two randomized controlled trials, J AM MED A, 282(4), 1999, pp. 331-340
Authors:
Schmid, DS
Brown, DR
Nisenbaum, R
Burke, RL
Alexander, D
Ashley, R
Pellett, PE
Reeves, WC
Citation: Ds. Schmid et al., Limits in reliability of glycoprotein G-based type-specific serologic assays for herpes simplex virus types 1 and 2, J CLIN MICR, 37(2), 1999, pp. 376-379
Authors:
McFarland, W
Gwanzura, L
Bassett, MT
Machekano, R
Latif, AS
Ley, C
Parsonnet, J
Burke, RL
Katzenstein, D
Citation: W. Mcfarland et al., Prevalence and incidence of herpes simplex virus type 2 infection among male Zimbabwean factory workers, J INFEC DIS, 180(5), 1999, pp. 1459-1465
Authors:
Frey, SE
Harrison, C
Pass, RF
Yang, E
Boken, D
Sekulovich, RE
Percell, S
Izu, AE
Hirabayashi, S
Burke, RL
Duliege, AM
Citation: Se. Frey et al., Effects of antigen dose and immunization regimens on antibody responses toa cytomegalovirus glycoprotein B subunit vaccine, J INFEC DIS, 180(5), 1999, pp. 1700-1703
Authors:
Pass, RF
Duliege, AM
Boppana, S
Sekulovich, R
Percell, S
Britt, W
Burke, RL
Citation: Rf. Pass et al., A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant, J INFEC DIS, 180(4), 1999, pp. 970-975
Authors:
Nesburn, AB
Burke, RL
Ghiasi, H
Slanina, SM
Wechsler, SL
Citation: Ab. Nesburn et al., Therapeutic periocular vaccination with a subunit vaccine induces higher levels of herpes simplex virus-specific tear secretory immunoglobulin A thansystemic vaccination and provides protection against recurrent spontaneousocular shedding of virus in latently infected rabbits, VIROLOGY, 252(1), 1998, pp. 200-209